Company Reports Revenue Improvement and Positive Data on Pipeline Assets
NEW YORK, July 29, 2022 /PRNewswire/ -- Q BioMed Inc. (OTCQB:QBIO) a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, has seen an uptick in Strontium89 sales revenue in its recently reported quarter. Revenue in Q2 was up 100% vs Q1 representing the best sales number to date. The company's pipeline also had some very positive news on its liver cancer drug adding significant value to the promise of that potential chemotherapeutic drug.
Read more at prnewswire.com
/Nike%2C%20Inc_%20swish%20by-%20Tartezy%20via%20Shutterstock.jpg)
/Server%20racks%20by%20dotshock%20via%20Shutterstock.jpg)
/AI%20(artificial%20intelligence)/Businessman%20touching%20the%20brain%20working%20of%20Artificial%20Intelligence%20(AI)%20Automation%20by%20Suttiphong%20Chandaeng%20via%20Shutterstock.jpg)